Drug intelligence / Profile preview

docetaxel + motesanib

Development stage: Unknown
Lead developer: Amgen
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

Docetaxel + motesanib is a combination therapy consisting of docetaxel, a chemotherapy medication that acts as a microtubule inhibitor, and motesanib, an investigational agent. This combination has been studied in phase 1b clinical trials for metastatic breast cancer. The maximum tolerated dose was established as motesanib 125 mg once daily when combined with docetaxel 100 mg/m² administered every 21 days. The combination showed an objective response rate of 56% among patients with measurable disease at baseline.

Targets

TUBB (Tubulin (alpha and beta subunits))VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR3 (Vascular endothelial growth factor receptor 3)PDGFRB (Platelet-derived growth factor receptor beta)VEGFR2 (Vascular endothelial growth factor receptor 2)KIT (c-KIT proto-oncogene receptor tyrosine kinase)

Beyond the preview

Go deeper on docetaxel + motesanib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on docetaxel + motesanib.

Explore the full profile